Literature DB >> 12771529

Inflammation in uremic patients: what is the link?

Jan Galle1, Stefan Seibold, Christoph Wanner.   

Abstract

Uremic patients suffer to an extremely high degree from cardiovascular disease. Cardiovascular disease results mainly from atherosclerotic remodeling of the arterial system. Inflammation is considered to contribute significantly to development of atherosclerosis, and albeit many different factors may lead to inflammation, generation of enhanced oxidative stress is believed to be an important common feature of pro-inflammatory causes. Studies in the general population without renal disease could clearly show that markers of inflammation, in particular C-reactive protein, predict the cardiovascular risk. In this review article, we discuss the presence and the predictive value of inflammation in patients with end-stage renal disease, and analyze whether uremic patients are exposed to specific pro-inflammatory and pro-oxidative conditions. Particular emphasis is set on oxidative stress induced by oxidatively modified lipoproteins and angiotensin II. Based on pathophysiological considerations valid for uremic patients, we discuss therapeutical options that might help to reduce cardiovascular disease in uremic patients. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771529     DOI: 10.1159/000070986

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials.

Authors:  Min Jun; Jicheng Lv; Vlado Perkovic; Meg J Jardine
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

2.  Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis.

Authors:  Jamshid Roozbeh; Bahram Shahriyari; Masoumeh Akmali; Ghazal Vessal; Maryam Pakfetrat; Ghanbar Ali Raees Jalali; Raha Afshariani; Mahshid Hasheminasab; Nasrollah Ghahramani
Journal:  Ren Fail       Date:  2011       Impact factor: 2.606

3.  No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients.

Authors:  Leszek Tylicki; Bogdan Biedunkiewicz; Dominik Rachon; Tomasz Nieweglowski; Lukasz Hak; Andrzej Chamienia; Alicja Debska-Slizien; Ewa Aleksandrowicz; Jolanta Mysliwska; Boleslaw Rutkowski
Journal:  Mediators Inflamm       Date:  2004-12       Impact factor: 4.711

4.  p-Cresol affects reactive oxygen species generation, cell cycle arrest, cytotoxicity and inflammation/atherosclerosis-related modulators production in endothelial cells and mononuclear cells.

Authors:  Mei-Chi Chang; Hsiao-Hua Chang; Chiu-Po Chan; Sin-Yuet Yeung; Hsiang-Chi Hsien; Bor-Ru Lin; Chien-Yang Yeh; Wan-Yu Tseng; Shui-Kuan Tseng; Jiiang-Huei Jeng
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

5.  Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia.

Authors:  Ingrid Wiswedel; Daniela Peter; Andreas Gardemann; Francesco Carluccio; Hannelore Hampl; Werner Siems
Journal:  Biomark Insights       Date:  2008-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.